{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T15:43:17Z","timestamp":1758469397381,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nursing Clinics of North America"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cnur.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T01:56:14Z","timestamp":1686880574000},"page":"389-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pharmacologic Update"],"prefix":"10.1016","volume":"58","author":[{"given":"Elizabeth","family":"Radchik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciantel A.","family":"Blyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cnur.2023.05.006_bib1","doi-asserted-by":"crossref","first-page":"e00","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics \u2013 2023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cnur.2023.05.006_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study (Coronary Artery Risk Development in [young] adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cnur.2023.05.006_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.cnur.2023.05.006_bib4","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.cnur.2023.05.006_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cnur.2023.05.006_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pfluegers Arch"},{"issue":"39","key":"10.1016\/j.cnur.2023.05.006_bib7","first-page":"2733","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"European Society of Cardiology (ESC)"},{"issue":"7","key":"10.1016\/j.cnur.2023.05.006_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"year":"2022","series-title":"Camzyos (mavacamten) [prescribing information]","key":"10.1016\/j.cnur.2023.05.006_bib9"},{"issue":"6273","key":"10.1016\/j.cnur.2023.05.006_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"suppl 1","key":"10.1016\/j.cnur.2023.05.006_bib11","article-title":"In\u00a0vivo cardiac effects of mavacamten (MYK-461): evidence for negative inotropy and improved compliance","volume":"136","author":"Del Rio","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.cnur.2023.05.006_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10253","key":"10.1016\/j.cnur.2023.05.006_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cnur.2023.05.006_bib14","unstructured":"Rader F. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy \u2013 EXPLORER-HCM. Presented at the American College of Cardiology Annual Scientific Session; April 3, 2022; Washington DC. Available at: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2020\/08\/28\/16\/14\/explorer-hcm. Accessed October 15, 2022."},{"issue":"21","key":"10.1016\/j.cnur.2023.05.006_bib15","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cnur.2023.05.006_bib16","article-title":"Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: Outcomes through 32-weeks","author":"Desai","year":"2022","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.cnur.2023.05.006_bib17","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"Suppl 1","key":"10.1016\/j.cnur.2023.05.006_bib18","first-page":"2","article-title":"Aficamten: A cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"10","author":"Elliott","year":"2022","journal-title":"EMJ Cardiol"},{"key":"10.1016\/j.cnur.2023.05.006_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012\u00a0United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cnur.2023.05.006_bib20","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.cnur.2023.05.006_bib21","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.cnur.2023.05.006_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cnur.2023.05.006_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practice criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"issue":"6807","key":"10.1016\/j.cnur.2023.05.006_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.cnur.2023.05.006_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"22","key":"10.1016\/j.cnur.2023.05.006_bib26","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cnur.2023.05.006_bib27","doi-asserted-by":"crossref","first-page":"bvaa122","DOI":"10.1210\/jendso\/bvaa122","article-title":"Management of familial hypercholesterolemia: current status and future perspectives","volume":"5","author":"Lui","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"issue":"24","key":"10.1016\/j.cnur.2023.05.006_bib28","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"year":"2021","series-title":"Leqvio (inclisiran) [prescribing inf","key":"10.1016\/j.cnur.2023.05.006_bib29"},{"issue":"1","key":"10.1016\/j.cnur.2023.05.006_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.cnur.2023.05.006_bib31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.cnur.2023.05.006_bib32","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.cnur.2023.05.006_bib33","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications - a cross national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cnur.2023.05.006_bib34","first-page":"e894","article-title":"2022 ACC\/AHA\/HFSA guidelines for management of heart failure","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cnur.2023.05.006_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cnur.2023.05.006_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cnur.2023.05.006_bib37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021\u00a0Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction","volume":"77","author":"Maddox","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cnur.2023.05.006_bib38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cnur.2023.05.006_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"year":"2021","series-title":"Aldactone (spironolactone) [prescribing information]","key":"10.1016\/j.cnur.2023.05.006_bib40"},{"key":"10.1016\/j.cnur.2023.05.006_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cnur.2023.05.006_bib42","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cnur.2023.05.006_bib43","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cnur.2023.05.006_bib44","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cnur.2023.05.006_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"year":"2023","series-title":"Farxiga (dapagliflozin) [prescribing information]","key":"10.1016\/j.cnur.2023.05.006_bib46"},{"year":"2021","series-title":"Jardiance (empagliflozin) [prescribing information]","key":"10.1016\/j.cnur.2023.05.006_bib47"},{"key":"10.1016\/j.cnur.2023.05.006_bib48","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cnur.2023.05.006_bib49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cnur.2023.05.006_bib50","first-page":"169","article-title":"Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists","volume":"7","author":"Vardeny","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"}],"container-title":["Nursing Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646523000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646523000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:41:58Z","timestamp":1758447718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0029646523000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0029646523000348"],"URL":"https:\/\/doi.org\/10.1016\/j.cnur.2023.05.006","relation":{},"ISSN":["0029-6465"],"issn-type":[{"type":"print","value":"0029-6465"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pharmacologic Update","name":"articletitle","label":"Article Title"},{"value":"Nursing Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cnur.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}